About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker VNDA · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Oct 19, 2026Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
NCT06836557 · Idiopathic Gastroparesis, Diabetic Gastroparesis
Tradipitant
VNDA
Vanda Pharmaceuticals
Phase 3Completed17Mar 30, 2026Registry ↗
Oct 9, 2026Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
NCT04652882 · Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm
Tasimelteon, Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Completed43Sep 4, 2026Registry ↗
Oct 6, 2026Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute…
NCT00254202 · Schizophrenia
Iloperidone, Ziprasidone
VNDA
Vanda Pharmaceuticals
Phase 3Completed593Sep 26, 2006Registry ↗
Oct 1, 2026Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCT05648591 · Schizophrenia, Bipolar I Disorder
Iloperidone
VNDA
Vanda Pharmaceuticals
Phase 4Recruiting100Dec 31, 2028Registry ↗
Sep 24, 2026Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Dep…
NCT06830044 · Major Depressive Disorder (MDD)
Milsaperidone, Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Recruiting500Mar 2028Registry ↗
Sep 24, 2026Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastropare…
NCT04028492 · Idiopathic Gastroparesis, Diabetic Gastroparesis
Tradipitant, Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Completed979Feb 21, 2025Registry ↗
Sep 22, 2026Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic…
NCT07362017 · Moderate-to-severe Chronic Plaque Psoriasis
Ponesimod
VNDA
Vanda Pharmaceuticals
Phase 3Recruiting300Aug 2028Registry ↗
Aug 19, 2026Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient
NCT07223632 · Charcot Marie Tooth Disease (CMT), Neuromuscular Diseases (…
VCA-894A
VNDA
Vanda Pharmaceuticals
Phase 1/2Active, not recruiting1Mar 2027Registry ↗
Aug 18, 2026Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Sev…
NCT07686081 · Ulcerative Colitis (UC)
Ponesimod, Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Recruiting150Apr 2029Registry ↗
Aug 17, 2026Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety…
NCT07221578 · Social Anxiety Disorder (SAD)
VQW-765, Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Active, not recruiting500Dec 2026Registry ↗
Jun 5, 2026Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869 · Insomnia Disorder
Tasimelteon Oral Suspension, Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Recruiting420Nov 2027Registry ↗
Apr 20, 2026A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
NCT07446439 · Nausea and Vomiting, Obesity
Tradipitant, Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Recruiting280Dec 1, 2026Registry ↗
Apr 16, 2026Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion S…
NCT06138613 · Motion Sickness
Tradipitant
VNDA
Vanda Pharmaceuticals
Phase 3Active, not recruiting705Sep 30, 2027Registry ↗
Mar 27, 2026Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Sub…
NCT05366855 · Generalized Pustular Psoriasis
Double-blind 200 mg imsidolimab, Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Terminated42Jul 12, 2024Registry ↗
Mar 17, 2026Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With…
NCT05352893 · Generalized Pustular Psoriasis
750 mg Imsidolimab, 300 mg Imsidolimab
VNDA
Vanda Pharmaceuticals
Phase 3Completed45Aug 17, 2023Registry ↗
Mar 16, 2026Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignanci…
NCT03838926 · Relapsed or Refractory Hematologic Malignancies
Trichostatin A
VNDA
Vanda Pharmaceuticals
Phase 1Recruiting42Dec 2027Registry ↗
Feb 27, 2026Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolle…
NCT07090161 · Hypertension, Uncontrolled Hypertension
iloperidone, Placebo
VNDA
Vanda Pharmaceuticals
Phase 2Recruiting240Oct 2026Registry ↗
Feb 4, 2026Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
NCT07065773 · Onychomycosis of Toenail
Trichostatin A
VNDA
Vanda Pharmaceuticals
Phase 2Active, not recruiting50Sep 2026Registry ↗
Jan 12, 2026Randomized Withdrawal Study in Patients With Schizophrenia
NCT06961968 · Schizophrenia
iloperidone, placebo
VNDA
Vanda Pharmaceuticals
Phase 3Recruiting400Nov 2027Registry ↗
Nov 12, 2025A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
NCT06804603 · Obesity
Tradipitant, Placebo
VNDA
Vanda Pharmaceuticals
Phase 2Completed124Oct 6, 2025Registry ↗
Sep 22, 2025A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participant…
NCT04856930 · Hidradenitis Suppurativa
Imsidolimab, Placebo
VNDA
Vanda Pharmaceuticals
Phase 2Completed149Jul 15, 2022Registry ↗
Sep 22, 2025A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participant…
NCT04856917 · Acne Vulgaris
Imsidolimab, Placebo
VNDA
Vanda Pharmaceuticals
Phase 2Completed123Feb 1, 2022Registry ↗
Sep 22, 2025A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneifor…
NCT04697069 · Acneiform Eruptions
Imsidolimab, Placebo
VNDA
Vanda Pharmaceuticals
Phase 2Terminated4Dec 13, 2021Registry ↗
Sep 19, 2025Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
NCT06494397 · Schizophrenia, Bipolar I Disorder
VHX-896 and iloperidone, Iloperidone and VHX-896
VNDA
Vanda Pharmaceuticals
Phase 1Completed26Oct 24, 2024Registry ↗
Sep 17, 2025An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treat…
NCT07179055 · Dry Eye
VSJ-110, Placebo
VNDA
Vanda Pharmaceuticals
Phase 2Recruiting160Sep 2026Registry ↗
Sep 16, 2025A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participant…
NCT04697056 · Ichthyosis
Imsidolimab, placebo
VNDA
Vanda Pharmaceuticals
Phase 2Terminated5Nov 19, 2021Registry ↗
Sep 16, 2025A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pust…
NCT03619902 · Generalized Pustular Psoriasis
Imsidolimab
VNDA
Vanda Pharmaceuticals
Phase 2Completed8Jan 20, 2021Registry ↗
Sep 15, 2025A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pus…
NCT03633396 · Palmoplantar Pustulosis
Imsidolimab, Placebo
VNDA
Vanda Pharmaceuticals
Phase 2Completed59Apr 23, 2021Registry ↗
Sep 11, 2025Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History…
NCT04622345 · Allergic Conjunctivitis
VSJ-110, Placebo
VNDA
Vanda Pharmaceuticals
Phase 2Completed47May 22, 2021Registry ↗
Aug 24, 2025Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis
NCT04474990 · Gastroparesis, Diabetic Gastroparesis
Tradipitant
VNDA
Vanda Pharmaceuticals
—Available——Registry ↗
May 9, 2025Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Si…
NCT03772340 · Motion Sickness
Tradipitant, Placebo
VNDA
Vanda Pharmaceuticals
Phase 2Completed126Jun 6, 2019Registry ↗
Apr 4, 2025Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Moti…
NCT05903924 · Motion Sickness
Tradipitant, Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Completed316Apr 6, 2024Registry ↗
Jan 31, 2025Food Effect Study of VHX-896 in Healthy Volunteers
NCT06803290 · Healthy
VHX-896
VNDA
Vanda Pharmaceuticals
Phase 1Completed24Dec 27, 2022Registry ↗
Dec 11, 2024Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sic…
NCT04327661 · Motion Sickness
Tradipitant, Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Completed366Apr 1, 2023Registry ↗
Nov 22, 2024Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and…
NCT06701396 · Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm
Tasimelteon, Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Recruiting60Jun 30, 2025Registry ↗
Aug 6, 2024Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
NCT02970968 · Gastroparesis
VLY-686 (Tradipitant), Placebo
VNDA
Vanda Pharmaceuticals
Phase 2Completed152Nov 2018Registry ↗
Jun 13, 2024Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
NCT02651714 · Atopic Dermatitis
Tradipitant, Placebo
VNDA
Vanda Pharmaceuticals
Phase 2Completed168Aug 4, 2017Registry ↗
Jun 11, 2024Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic De…
NCT02004041 · Treatment-resistant Pruritus Associated With Atopic Dermati…
VLY-686, Placebo
VNDA
Vanda Pharmaceuticals
Phase 2Completed69Feb 19, 2015Registry ↗
May 14, 2024Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
NCT04140695 · Atopic Dermatitis
Tradipitant, Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Terminated87Oct 14, 2020Registry ↗
May 13, 2024Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
NCT03568331 · Atopic Dermatitis
Tradipitant, Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Completed375Dec 27, 2019Registry ↗
Apr 18, 2024Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes…
NCT04819776 · Bipolar I Disorder
Iloperidone, Iloperidone Placebo
VNDA
Vanda Pharmaceuticals
Phase 3Completed417Sep 7, 2022Registry ↗
Apr 16, 2024Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in…
NCT04849559 · Healthy Volunteer
Tradipitant, Placebo
VNDA
Vanda Pharmaceuticals
Phase 1/2Completed27Sep 24, 2021Registry ↗
Apr 3, 2024Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals W…
NCT01218789 · Non 24 Hour Sleep Wake Disorder
tasimelteon
VNDA
Vanda Pharmaceuticals
Phase 3Unknown140Dec 5, 2024Registry ↗
Mar 22, 2024WGS Analysis of COVID-19 Positive Patients
NCT04353401 · Coronavirus Infection, COVID-19
VNDA
Vanda Pharmaceuticals
—Completed79Mar 9, 2022Registry ↗
Mar 21, 2024Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in…
NCT06323655 · Healthy Volunteers
Tasimelteon, Active Control Placebo
VNDA
Vanda Pharmaceuticals
Phase 1Completed48Aug 28, 2018Registry ↗
Mar 21, 2024Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in H…
NCT05572281 · Healthy
Tasimelteon Oral Capsule, Tasimelteon Oral Suspension
VNDA
Vanda Pharmaceuticals
Phase 1Completed36Jun 15, 2022Registry ↗
Mar 21, 2024Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep…
NCT05361707 · Autism Spectrum Disorder, Sleep Disorder
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
VNDA
Vanda Pharmaceuticals
Phase 3Unknown100Jul 2025Registry ↗
Mar 21, 2024A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
NCT05344365 · Parkinson Disease Psychosis
Iloperidone
VNDA
Vanda Pharmaceuticals
Phase 2Withdrawn0Nov 2023Registry ↗
Mar 21, 2024Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents
NCT02776215 · Circadian Rhythm Sleep Disorders, Non-24 Hour Sleep-Wake Di…
tasimelteon
VNDA
Vanda Pharmaceuticals
Phase 1Completed24Dec 20, 2017Registry ↗
Mar 20, 2024Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety
NCT04800237 · Performance Anxiety
VQW-765, Placebo
VNDA
Vanda Pharmaceuticals
Phase 2Completed230Aug 2, 2022Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:02 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances